Overview
- Top-line data from the EVOKE and EVOKE+ studies showed no statistically significant slowing of clinical progression versus placebo on measures such as the CDR‑SB.
- The randomized, double-blind trials enrolled 3,808 adults with mild cognitive impairment or mild dementia due to Alzheimer’s and tested oral semaglutide (Rybelsus) on top of standard care.
- Although some Alzheimer’s-related biomarkers improved, those changes did not translate into measurable clinical benefit.
- Novo Nordisk discontinued a planned one-year extension and characterized the program as a high-risk effort from the outset.
- Shares fell roughly 9%–12% to multi-year lows following the announcement; fuller datasets are slated for CTAD (Dec 1–4) and AD/PD in March 2026.